How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?  

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Wentworth Douglass Hospital
If the patient becomes non surgical due to his unr...
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
That's a good question. Especially since locally a...
Radiation Oncologist at SUNY Upstate Medical University
This is becoming more common, and the answer may c...
Sign in or Register to read more